FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BEAVER CAROLYN						2. Issuer Name and Ticker or Trading Symbol MEDICINOVA INC [MNOV] 3. Date of Earliest Transaction (Month/Day/Year)							eck all applic	10%		on(s) to Issu 10% Ow Other (sp	ner
(Last)	(Fi	st) (Middle)			06	06/11/2024							below)			below)	,,,,,
C/O MEDICINOVA, INC. 4275 EXECUTIVE SQUARE, SUITE 300						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person				
(Street) LA JOLLA CA		A	92037		D	ulo 1	10h5 :	1/0\	Tranca	ation Ind	ioation		Form f Persor		e than	One Report	ing
(City)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ear) i	2A. Deemed Execution Date, f any (Month/Day/Year		Transaction Dispose Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amour Securitie Beneficia Owned F Reported	s Formally (D) of collowing (I) (I		Direct C Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V	Amount	(A) or (D)	Price	Transact	nsaction(s) str. 3 and 4)			115(1.4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$1.34	06/11/2024			A		20,000		(1)	06/10/2034	Common Stock	20,000	\$0	20,000		D	

Explanation of Responses:

1. The option vests in four equal installments on September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025, subject to continued service with the Company.

/s/ Yuichi Iwaki, attorney-in-

fact

** Signature of Reporting Person Date

06/12/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.